Methods and compositions for treating and preventing disease associated with alpha-V beta-8 integrin

US9969804B2 · kind B2 · utility

Assignee

• The Regents of the University of California · US

Inventors

• Dean Sheppard · Oakland, US
• Amha Atakilit · San Francisco, US
• Neil Cowan Henderson · Edinburgh, GB

Key dates

• Filing date: Apr 1, 2014
• Grant date: May 15, 2018
• Expiry date: Aug 20, 2034

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/76
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Antibodies (e.g., isolated antibodies) that specifically bind to human integrin β8 and inhibit adhesion of latency associated peptide (LAP) to αvβ8 are provided. In some embodiments, the antibody cross-reacts with mouse integrin β8. In some embodiments, the antibody blocks TGFJ3 activation. In some embodiments, the antibody antagonizes binding of LAP to αβ8 with an IC50 below 5 nM.